1. Home
  2. BMEA vs TDUP Comparison

BMEA vs TDUP Comparison

Compare BMEA & TDUP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Biomea Fusion Inc.

BMEA

Biomea Fusion Inc.

HOLD

Current Price

$1.78

Market Cap

107.7M

Sector

Health Care

ML Signal

HOLD

Logo ThredUp Inc.

TDUP

ThredUp Inc.

HOLD

Current Price

$3.73

Market Cap

414.1M

ML Signal

HOLD

Company Overview

Basic Information
Metric
BMEA
TDUP
Founded
2017
2009
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Catalog/Specialty Distribution
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
107.7M
414.1M
IPO Year
2021
2021

Fundamental Metrics

Financial Performance
Metric
BMEA
TDUP
Price
$1.78
$3.73
Analyst Decision
Strong Buy
Buy
Analyst Count
7
4
Target Price
$8.86
$8.00
AVG Volume (30 Days)
1.6M
2.3M
Earning Date
05-04-2026
05-04-2026
Dividend Yield
N/A
N/A
EPS Growth
69.19
75.36
EPS
N/A
N/A
Revenue
N/A
$310,813,000.00
Revenue This Year
N/A
$15.67
Revenue Next Year
N/A
$10.04
P/E Ratio
N/A
N/A
Revenue Growth
N/A
19.53
52 Week Low
$0.87
$3.08
52 Week High
$3.07
$12.28

Technical Indicators

Market Signals
Indicator
BMEA
TDUP
Relative Strength Index (RSI) 66.92 50.61
Support Level $1.77 $3.08
Resistance Level $2.06 $5.27
Average True Range (ATR) 0.16 0.20
MACD 0.06 0.10
Stochastic Oscillator 76.76 86.00

Price Performance

Historical Comparison
BMEA
TDUP

About BMEA Biomea Fusion Inc.

Biomea Fusion Inc is a a clinical stage diabetes and obesity medicines company focused on the discovery and development of oral, small molecule drugs to treat and improve the lives of patients with diabetes, obesity, and other metabolic diseases. It operate as an organization centered on two of its core drug candidate development programs: (i) icovamenib, its clinical program's drug candidate, currently being developed as an orally bioavailable, and selective, covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity, and (ii) BMF-650, its investigational, next-generation oral glucagon-like peptide-1 GLP-1 receptor agonist in development for the treatment of obesity.

About TDUP ThredUp Inc.

ThredUp Inc is an online resale platform for apparel, shoes, and accessories. The company's marketplaces have enabled buyers in the United States ("U.S.") to browse and purchase resale items principally for apparel, shoes, and accessories across a range of price points. The company's revenue is principally from the sale of secondhand apparel, shoes, and accessories on behalf of sellers.

Share on Social Networks: